BIOCHEMICAL STUDY OF SERUM β-HYDROXYBUTYRATE DEHYDROGENASE IN β-THALASSEMIA

Q3 Pharmacology, Toxicology and Pharmaceutics
Hiba Sami, M. Fakhri
{"title":"BIOCHEMICAL STUDY OF SERUM β-HYDROXYBUTYRATE DEHYDROGENASE IN β-THALASSEMIA","authors":"Hiba Sami, M. Fakhri","doi":"10.31482/mmsl.2022.013","DOIUrl":null,"url":null,"abstract":"Introduction: Thalassemia is a healthcare challenging disease all over the world. It imparts a great burden on patients’ families and healthcare institutions. Scientists focus on new aspects to overcome these challenges and increase patient tolerance of disease complications. This study aims to quantify β-Hydroxybutyrate Dehydrogenase BHBDH activity in thalassemia patients compared to the control group and their correlation with the patient's demographic characteristics. Methods: To do so, serum was collected from patients and the control group and analyzed biochemically for targeted laboratory tests. We determined β-Hydroxybutyrate Dehydrogenase from normal human serum using biochemical molecular techniques. Results: The results showed that BHBDH activity is significantly higher in the patients compared to the control group regardless of age, sex, or marital status. The results confirmed that enzyme activity and the purification folds were (0.0214 U/ml) and (51.7) respectively for the partially purified enzyme. Furthermore, the proportional molecular weight of the incompletely isolated β-Hydroxybutyrate Dehydrogenase was (125.8±0.5 kDa) using gel filtration chromatography. The comparative molecular weight of the subunit of partially isolated β-Hydroxybutyrate Dehydrogenase was (32.1±0.5 kDa) using SDS–PAGE. Conclusion: we demonstrate that BHBDH enzymatic activity is higher than control and this could be a prognostic or diagnostic tool in thalassemia patients.","PeriodicalId":38749,"journal":{"name":"Vojenske Zdravotnicke Listy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vojenske Zdravotnicke Listy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31482/mmsl.2022.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Thalassemia is a healthcare challenging disease all over the world. It imparts a great burden on patients’ families and healthcare institutions. Scientists focus on new aspects to overcome these challenges and increase patient tolerance of disease complications. This study aims to quantify β-Hydroxybutyrate Dehydrogenase BHBDH activity in thalassemia patients compared to the control group and their correlation with the patient's demographic characteristics. Methods: To do so, serum was collected from patients and the control group and analyzed biochemically for targeted laboratory tests. We determined β-Hydroxybutyrate Dehydrogenase from normal human serum using biochemical molecular techniques. Results: The results showed that BHBDH activity is significantly higher in the patients compared to the control group regardless of age, sex, or marital status. The results confirmed that enzyme activity and the purification folds were (0.0214 U/ml) and (51.7) respectively for the partially purified enzyme. Furthermore, the proportional molecular weight of the incompletely isolated β-Hydroxybutyrate Dehydrogenase was (125.8±0.5 kDa) using gel filtration chromatography. The comparative molecular weight of the subunit of partially isolated β-Hydroxybutyrate Dehydrogenase was (32.1±0.5 kDa) using SDS–PAGE. Conclusion: we demonstrate that BHBDH enzymatic activity is higher than control and this could be a prognostic or diagnostic tool in thalassemia patients.
β地中海贫血患者血清β-羟基丁酸脱氢酶的生化研究
地中海贫血是一种全球性的具有挑战性的疾病。它给患者家庭和医疗机构带来了巨大的负担。科学家们专注于新的方面来克服这些挑战,并提高患者对疾病并发症的耐受性。本研究旨在量化地中海贫血患者与对照组相比β-羟基丁酸脱氢酶BHBDH活性及其与患者人口统计学特征的相关性。方法:采集患者和对照组血清,进行生化分析,进行针对性实验室检测。我们用生化分子技术测定了正常人血清中β-羟基丁酸脱氢酶。结果:结果显示,无论年龄、性别、婚姻状况如何,患者的BHBDH活性均明显高于对照组。结果表明,部分纯化酶的酶活和纯化倍数分别为(0.0214 U/ml)和(51.7)。凝胶过滤层析得到未完全分离的β-羟基丁酸脱氢酶的比例分子量为(125.8±0.5 kDa)。部分分离得到的β-羟基丁酸脱氢酶亚基相对分子量为(32.1±0.5 kDa)。结论:我们证明bhbhdh酶活性高于对照组,这可能是地中海贫血患者的预后或诊断工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vojenske Zdravotnicke Listy
Vojenske Zdravotnicke Listy Health Professions-Emergency Medical Services
CiteScore
1.00
自引率
0.00%
发文量
41
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信